{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124626","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.093865+00:00","generated_at":"2026-05-30T02:31:23.452271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Therapeutics reports Q3 net product sales of $32.8M; narrows FY2024 guidance to positive Adj EBITDA","bullets":["Q3 acute care franchise net product sales $7.4M (+57% YoY); oncology franchise $25.4M (-5% YoY).","YTD Adjusted EBITDA positive at $1.4M; FY2024 Adj EBITDA guidance narrowed to $2M-$5M (from $(10)-$3M).","ZYNRELEF VAN approved Sep 24, on track for Q4 launch; CMS final rule includes ZYNRELEF for separate payment ($2,267.26 limit) through at least 2027.","Cash and equivalents $70.9M at Sep 30, 2024 vs $80.4M at Dec 31, 2023.","Total net product sales for first 9 months 2024: $103.5M vs $92.8M in prior year period."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124626","json":"https://secwatch.observer/filing/0000950170-24-124626.json","markdown":"https://secwatch.observer/filing/0000950170-24-124626.md","text":"https://secwatch.observer/filing/0000950170-24-124626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/0000950170-24-124626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017024124626/hrtx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:31:23.452271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}